

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-118. (cancelled)

119. (currently amended) An isolated native sequence polypeptide having at least 80% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:351;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:351, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209982,  
~~wherein the nucleic acid encoding said polypeptide is amplified in adenocarcinomas or squamous cell carcinomas of lung.~~

120. (currently amended) The isolated native sequence polypeptide of Claim 119 having at least 85% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:351;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:351, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209982,  
~~wherein the nucleic acid encoding said polypeptide is amplified in adenocarcinomas or squamous cell carcinomas of lung.~~

121. (currently amended) The isolated native sequence polypeptide of Claim 119 having at least 90% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:351;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:351, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209982,

~~wherein the nucleic acid encoding said polypeptide is amplified in adenocarcinomas or squamous cell carcinomas of lung.~~

122. (currently amended) The isolated native sequence polypeptide of Claim 119 having at least 95% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:351;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:351, lacking its associated signal peptide;

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209982,

~~wherein the nucleic acid encoding said polypeptide is amplified in adenocarcinomas or squamous cell carcinomas of lung.~~

123. (currently amended) The isolated native sequence polypeptide of Claim 119 having at least 99% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:351;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:351, lacking its associated signal peptide,

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209982,

~~wherein the nucleic acid encoding said polypeptide is amplified in adenocarcinomas or squamous cell carcinomas of lung.~~

124. (currently amended) An isolated polypeptide comprising:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:351;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:351, lacking its associated signal peptide,

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209982,

~~wherein the nucleic acid encoding said polypeptide is amplified in adenocarcinomas or squamous cell carcinomas of lung.~~

125. (previously presented) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide of SEQ ID NO:351.

126. (previously presented) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide of SEQ ID NO:351, lacking its associated signal peptide.

127-128. (canceled)

129. The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209982.

130. A chimeric polypeptide comprising a polypeptide according to Claim 124 fused to a heterologous polypeptide.

131. The chimeric polypeptide of Claim 130, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.